Trial Profile
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Mobocertinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept; Registrational; Therapeutic Use
- Acronyms EXCLAIM
- Sponsors Takeda; Takeda Oncology
- 17 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Results assessing efficacy patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 26 May 2023 According to a Foundation Medicine media release, data from this trial will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.